Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10417018" target="_blank" >RIV/00216208:11110/20:10417018 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/20:10417018
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=nRiU-a8zSw" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=nRiU-a8zSw</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.autrev.2020.102671" target="_blank" >10.1016/j.autrev.2020.102671</a>
Alternative languages
Result language
angličtina
Original language name
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Original language description
Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial immunosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-initiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off-label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions concerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to overcome these limitations.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Autoimmunity Reviews
ISSN
1568-9972
e-ISSN
—
Volume of the periodical
19
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
102671
UT code for WoS article
000579751000010
EID of the result in the Scopus database
2-s2.0-85091214005